Generics - Oncology, Biotechnology

Filter

Current filters:

OncologyBiotechnology

Popular Filters

US firms establish strategic partnership around biosimilars

06-08-2013

Privately-held Oncobiologics has formed a broad strategic partnership with fellow USA-based inVentiv…

AvastinBiotechnologyErbituxGenericsHerceptinHumiraImmunologicalsinVentive HealthOncobiologicsOncologyProductionResearchRituxan

Hospira's biosimilar epoetin meets primary endpoints in post-marketing study

04-06-2013

Leading provider of injectable drugs and infusion technologies Hospira (NYSE: HSP) says that results…

BiotechnologyepoetinGenericsOncologyResearchRetacrit

Cancer treatments "unaffordable" and will drive rapid transition to generics and market decline, says GlobalData

10-05-2013

The rising prices of new cancer drugs are resulting in an increasing cost burden for patients and health…

BiotechnologyGenericsGlobalMarkets & MarketingOncologyPharmaceuticalPricing

Russia's Biocad plans to produce high-tech drugs in Brazil

19-03-2013

Biocad, one of Russia's leading biotechnology companies, plans to launch production of several of its…

AvastinBiocadBiotechnologyGenericsHerceptinMabTheraOncologyProductionRocheSouth America

Aduro BioTech buys all GVAX assets from BioSante; Aspen in talks to buy Merck unit

05-02-2013

Aduro BioTech, a privately-held, US venture capital backed biotechnology company, says it has acquired…

Aduro BioTechAspen PharmacareBioSante PharmaceuticalsBiotechnologyGenericsGVAXImmunologicalsMerck & CoMergers & AcquisitionsOncologyVaccines

Generics and biosimilars will lead to decline in colorectal cancer market from $8.3 billion in 2011 to $7.8 billion in 2021

04-11-2012

Through 2021, growth in the market for colorectal cancer (CRC) treatments will decline in the face of…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

Biosimilar versions of MAbs for cancer forecast to garner sales of $4.9 billion in 2021

28-10-2012

While branded versions of monoclonal antibodies for cancer are expected to maintain sales of $6.7 million…

BiotechnologyGenericsGlobalMarkets & MarketingOncology

FDA approves pediatric Afinitor from Novartis and Teva's tbo-filgrastim

30-08-2012

The US Food and Drug Administration yesterday approved Swiss drug major Novartis' (NOVN: VX) Afinitor…

AfinitorBiotechnologyGenericsNorth AmericaNovartisOncologyPharmaceuticalRegulationSicor Biotechtbo-filgrastimTeva Pharmaceutical Industries

Merck KGaA collaborates with Dr Reddy's on biosimilars

07-06-2012

With the aim of capitalizing on the batch of patent expires for blockbuster biotechnology-based drugs…

BiotechnologyDr Reddy's LaboratoriesGenericsMarkets & MarketingMerck KGaAMerck SeronoOncologyResearch

News briefs: Genmab/GSK, Gilead and Mylan

24-05-2012

Denmark's Genmab (OMX: GEN) yesterday received a milestone payment of 20 million Danish kroner ($3.4…

Anti-viralsBiotechnologycobicistatFinancialGenericsGenmabGilead SciencesGlaxoSmithKlineMylan LaboratoriesOncologyRegulationViramune

Sandoz initiates two more Phase III biosimilar trials

20-01-2012

Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX), says that it has initiated two milestone…

AmgenBiotechnologyFilgrastimGenericsNovartisOncologypegfilgrastimResearchSandozZarzio

Hospira progresses biosimilar Epogen

11-01-2012

USA-based Hospira (NYSE: HSP), a leading provider of generic injectable drugs and infusion technologies,…

AmgenBiotechnologyEpogenerythropoietinGenericsHospiraNephrology and HepatologyOncologyResearch

Amgen in cancer biosimilars deal with Watson

20-12-2011

A collaboration has been entered into by Amgen (Nasdaq: AMGN), the world’s largest independent biotech…

AmgenBiotechnologyGenericsGlobalLicensingMarkets & MarketingOncologyWatson Pharmaceuticals

Some 40% of G7 ESA markets to be biosimilars by 2020, and insulins to reach $1 billion, says DR report

30-10-2011

By 2020, biosimilar versions of erythropoietin stimulating agents (ESAs) will garner 40% market share…

BiotechnologyDiabetesGenericsGlobalMarkets & MarketingOncology

Glycotope enrolls first patient for “biobetter” of Roche cancer drug Herceptin

20-09-2011

Berlin, Germany-based glycomics specialist Glycotope GmbH says it has enrolled the first patients in…

BiotechnologyGenericsGlycotopeHerceptinOncologyResearchRochetrastuzumab

Back to top